VOLUME 62   2001   NUMBER 4

Commentary

221 The Need for Clinically Relevant Research on Treatment-Resistant Depression. Michael E. Thase
[PDF]

Brainstorms

225 Why Drugs and Hormones May Interact in Psychiatric Disorders. Stephen M. Stahl
[PDF]

Original Articles

227 Bupropion Sustained Release for Bereavement: Results of an Open Trial. Sidney Zisook, Stephen R. Shuchter, Paola Pedrelli, Jeremy Sable, and Simona C. Deaciuc
[Abstract] [PDF]

231 Factors Influencing Acute Weight Change in Patients With Schizophrenia Treated With Olanzapine, Haloperidol, or Risperidone. Bruce R. Basson, Bruce J. Kinon, Cindy C. Taylor, Keith A. Szymanski, Julie A. Gilmore, and Gary D. Tollefson
[Abstract] [PDF]

239 A Randomized Controlled Trial of Risperidone in the Treatment of Aggression in Hospitalized Adolescents With Subaverage Cognitive Abilities. Jan K. Buitelaar, Rutger Jan van der Gaag, Peggy Cohen-Kettenis, and Caroline T. M. Melman
[Abstract] [PDF]

249 Antidepressant-Induced Mania in Bipolar Patients: Identification of Risk Factors. Chantal Henry, Frederic Sorbara, Jerome Lacoste, Claire Gindre, and Marion Leboyer
[Abstract] [PDF]

256 Effects of Nefazodone on Body Weight: A Pooled Analysis of Selective Serotonin Reuptake Inhibitor­ and Imipramine-Controlled Trials. Norman Sussman, David L. Ginsberg, and Jessica Bikoff
[Abstract] [PDF]

261 Health-Related Quality-of-Life Measure Enhances Acute Treatment Response Prediction in Depressed Inpatients. Jeffrey M. Pyne, Dale Bullock, Robert M. Kaplan, Thomas L. Smith, J. Christian Gillin, Shahrokh Golshan, John R. Kelsoe, and D. Keith Williams
[Abstract] [PDF]

269 Smoking Habits in Bipolar and Schizophrenic Outpatients in Southern Israel. Olga Itkin, Boris Nemets, and Haim Einat
[Abstract] [PDF]

273 Long-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder: An Open-Label Continuation Phase Study. Todd M. Sanger, Starr L. Grundy, P. Joseph Gibson, Madhav A. Namjoshi, Michael G. Greaney, and Mauricio F. Tohen
[Abstract] [PDF]

282 Optimal Dosing With Risperidone: Updated Recommendations. Richard Williams
[Abstract] [PDF]

290 An Open-Label Study of the Treatment Efficacy of Olanzapine for Tourette's Disorder. Cathy L. Budman, Alex Gayer, Martin Lesser, Qiuhu Shi, and Ruth D. Bruun
[Abstract] [PDF]

CME Article 303

304 Use of the Brief Psychiatric Rating Scale to Facilitate Differential Diagnosis at Acute Inpatient Admission. Derek R. Hopko, Patricia M. Averill, David Small, Helen Greenlee, and Roy V. Varner
[Abstract] [PDF]

Letters to the Editor

295 Cost Savings With Intramuscular Anticholinergics. John S. Markowitz, Stephen McLeod-Bryant, and Cherry Wyant Jackson
[PDF]

295 Problems With Ensuring a Double Blind. Shailesh Kumar and Mark Oakley-Browne
[PDF]

  • Reply by Raffaella Zanardi, David Rossini, and Alessandro Serretti

296 Low-Dose Olanzapine for Self-Mutilation Behavior in Patients With Borderline Personality Disorder. David W. Hough
[PDF]

297 Successful Treatment of Nondelusional Body Dysmorphic Disorder With Olanzapine: A Case Report. Jon E. Grant
[PDF]

298 Olanzapine in the Treatment of Tardive Dyskinesia: A Report of 2 Cases. Vivek Agarwal and Parvesh Kumar
[PDF]

Book Reviews 300

Information for authors

see January 2001, pages 75­77 or our Web site at www.psychiatrist.com/author.htm